BridgeBio Oncology Therapeutics, Inc.
No enriched coverage for $BBOT in the last 7 days.
No SEC Form 4 filings for $BBOT in the last 30 days.
BridgeBio Oncology Therapeutics, Inc. (BBOT) has registered 63.05 million common shares for resale by existing securityholders through a post-effective amendment to its Form S-1. These shares include PIPE shares, shares issued during the Business Combination, and shares issuable upon option exercise. The company will not receive proceeds from these resales, except if options are exercised for cash.
BridgeBio Oncology Therapeutics (NASDAQ: BBOT) announced that two new employees hired in January 2026 were awarded 65,350 non-qualified stock options on February 10, 2026. The options have an exercise price of $10.84 per share and will vest 25% after one year, then monthly over 36 months, according to the company's 2025 Inducement Plan. This grant, approved by the compensation committee, is in compliance with Nasdaq Listing Rule 5635(c)(4).
SOUTH SAN FRANCISCO, Calif., Oct. 25, 2025 ( GLOBE NEWSWIRE ) -- BridgeBio Oncology Therapeutics, Inc. ( "BBOT" ) ( Nasdaq: BBOT ) , a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced new preclinical data showing BBO-10203 selectively and specifically ...
